Company intelligence / Profile preview

PARI Pharma

Starnberg, Bavaria, Germanypari.com ↗

Ownership: Private
Development stage: Commercial

Overview

PARI Pharma develops and commercializes advanced inhalation devices and partners with pharmaceutical companies to deliver both proprietary and partner drugs via its eFlow vibrating membrane nebulizer platform. The company’s focus on optimizing drug-device combinations has led to improved therapeutic efficiency for several respiratory diseases. Clinical results are not detailed in public sources but the company’s products are widely used globally in both clinical practice and at home settings

Therapeutic areas: Pulmonology
Modalities: DeviceSmall moleculeBiologic
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Buparid

Unknown

Partnerships

Collaborates with pharmaceutical industry partners

Beyond the preview

Go deeper on PARI Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PARI Pharma.

Explore the full profile